dosimertinib / Genuine Biotech - LARVOL DELTA

Beyond the standard 80 mg: Exposure-guided and equity-oriented precision dosing of Osimertinib in EGFR-mutant NSCLC. (PubMed, J Oncol Pharm Pract) - "BackgroundOsimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has become foundational therapy across the EGFR-mutant non-small cell lung cancer (NSCLC) continuum, including first-line metastatic disease, unresectable stage III consolidation, and adjuvant therapy after resection. However, existing datasets remain heterogeneous, and no globally accepted therapeutic range exists.ConclusionsOsimertinib precision dosing is an emerging, plausible, and equity-relevant paradigm-especially in India and other resource-constrained settings-but requires prospective, locally anchored therapeutic window studies, pragmatic TDM workflows, and model-informed dose adaptation trials before routine implementation. Pending such evidence, exposure-guided dosing should be regarded as investigational rather than standard care."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Azvudine combined with Doxitinib, a potential therapy for EGFRm+ NSCLC (AACR 2026) - P1/2 | "In vivo, the combination achieved superior tumor growth inhibition compared to either monotherapy in the NCI-H1975 (EGFR L858R/T790M) xenograft model.Collectively, these findings suggest that the combination of FNC and Doxitinib represents a promising therapeutic strategy to enhance efficacy and overcome acquired resistance in EGFRm⁺ NSCLC. Based on these preclinical and clinical findings, a phase 1/2 clinical trial will be initiated to evaluate the safety and efficacy of this combination therapy in EGFR-mutant NSCLC patients."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8

Navigating the deuteration landscape: innovations, challenges, and clinical potential of deuterioindoles. (PubMed, Chembiochem) - "This review elucidates the progression of deuterium chemistry, culminating in approval of Deutetrabenazine in 2017. This milestone has catalyzed additional research into deuterated indoles, such as Dosimertinib, which have demonstrated enhancements in stability, toxicity profiles, and therapeutic efficacy. Moreover, the review addresses challenges and patent issues in the synthesis of deuterated indoles and highlights their potential applications in precision medicine. In the future, deuterated indoles may positively impact therapy and contribute to advances in precision medicine through molecular engineering."

Journal • Targeted Protein Degradation